NanoViricides, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2022; filed October 13, 2022. The request metadata says “2021 Q4,” but the filing is for FY2022, not that quarter.
Business context
NanoViricides is a development-stage antiviral drug company with no approved products, customers, or revenue. Its lead programs are NV-CoV-2 and NV-CoV-2-R for COVID-19; the shingles candidate NV-HHV-1 is another advanced program. The company describes NV-CoV-2’s preclinical safety and efficacy work as completed and was preparing an IND and clinical protocols, but had not begun human trials. Its candidates and platform claims remain unproven in people.
Financial performance and position
| Metric | FY2022 / June 30, 2022 | FY2021 / June 30, 2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $5.78 million | $6.11 million |
| General and administrative expense | $2.33 million | $2.63 million |
| Total operating expenses | $8.11 million | $8.74 million |
| Net loss | $8.11 million; $0.70 per share | $8.82 million; $0.81 per share |
| Net cash used in operating activities | $5.89 million | $8.21 million |
| Cash and cash equivalents | $14.07 million | $20.52 million |
| Working capital | $14.00 million | $20.47 million |
| Total assets / stockholders’ equity | $23.49 million / $23.08 million | $30.26 million / $29.91 million |
| Current liabilities / long-term liabilities | $0.41 million / $0 | $0.35 million / $0 |
With no revenue, gross margins and operating margins are not meaningful. The net loss narrowed by $0.72 million year over year, mainly as operating and interest expenses declined. Cash fell by $6.45 million during FY2022; the company reported no financing proceeds that year, versus $16.56 million of net financing proceeds in FY2021. It reported approximately $0.32 million of capital spending in FY2022. Accumulated deficit reached $122.49 million.
Management said available cash was expected to fund planned operations through October 2023 and estimated roughly $10 million of spending from July 2022 through October 2023. It also estimated that a further approximately $14 million could be needed for subsequent development plans. These are estimates, not committed funding. The company reported a $94,788 short-term insurance-premium loan and no long-term debt.
Material changes and notable items
- R&D expense declined about 5% and G&A expense about 11% from FY2021. Management attributed the R&D decrease mainly to lower lab supplies, compensation and pre-IND fees, partly offset by a license fee; lower legal and professional costs reduced G&A.
- COVID-19 development absorbed nearly all R&D spending: approximately $5.68 million of FY2022 R&D was allocated to COVID-19, versus $5.56 million in FY2021. HerpeCide spending fell to $0.10 million from $0.55 million.
- The company issued 100,000 Series A preferred shares to related party TheraCour under the COVID-19 license and recorded $935,088 of R&D expense. TheraCour charged $2.37 million in development and other costs during FY2022; $214,397 was reported payable at year-end. The license provides for milestone payments and 15% of net sales or sublicensing income.
- The company’s common shares outstanding increased to 11.59 million from 11.52 million. It also issued shares for compensation and services. A previously authorized ATM program of up to $50 million remained available, but future sales and dilution are not assured.
- Management disclosed ineffective disclosure controls and a material weakness in financial reporting controls due to insufficient personnel/resources and inadequate, untimely review of the period-end close and filings. A management and Audit Committee financial reporting controls committee was established as a remediation measure; remediation was not yet demonstrated as complete at year-end.
Outlook, risks and contingencies
- Management aimed to complete the NV-CoV-2 IND and initiate Phase I/IIa trials in FY2023, including potentially pursuing trials outside the United States. The filing gives no assured timeline and expressly notes dependence on CRO availability, regulatory steps, staffing and financing. The expected trial start was a plan, not guidance or a guarantee.
- The company estimated $0.5 million to $1.5 million for initiating Phase I/IIa trials, while its broader near-term budget included clinical-batch, research, trial and corporate costs. It said additional capital would be required for later-stage trials and further pipeline development; potential equity financing could dilute shareholders.
- Key risks include clinical failure or delay, regulatory rejection, inability to raise capital, limited staffing, reliance on outside CROs and other collaborators, and the lack of commercial manufacturing scale, sales and marketing capabilities. The company has never conducted human trials or generated revenue.
- TheraCour is a critical technology and development provider controlled approximately 90% by founder and CEO Anil Diwan. The related-party relationship, milestone and royalty obligations, and governance conflicts merit attention. Dr. Diwan’s spouse is the CFO; the filing states he recuses himself from certain related-party decisions.
- The company reported no material legal proceedings and no off-balance-sheet arrangements. Its financial statements received an unqualified audit opinion; the auditor identified related-party transactions as a critical audit matter. The audit did not provide an opinion on internal-control effectiveness.
Most important facts for investors to verify
- Whether an IND was actually filed and cleared, and whether human trials began, their design, enrollment, and independently reported results.
- Actual cash burn, subsequent financing, and whether the stated runway and clinical-development budgets remain achievable.
- Progress in remediating the material weakness and the effectiveness of financial reporting controls in later filings.
- TheraCour charges, outstanding balances, license milestones, preferred-share voting rights, and the company’s ability to retain its licensed rights.
- Whether preclinical findings translate to human safety and efficacy; management’s claims of broad-spectrum activity and potential clinical benefit are not clinical evidence.
- Potential dilution from the ATM facility, outstanding securities and future capital needs, as well as the terms of any commercial-scale manufacturing arrangements.